Literature DB >> 24647050

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

Lesley A Inker1, Brad C Astor2, Chester H Fox3, Tamara Isakova4, James P Lash5, Carmen A Peralta6, Manjula Kurella Tamura7, Harold I Feldman8.   

Abstract

The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guideline for evaluation, classification, and stratification of chronic kidney disease (CKD) was published in 2002. The KDOQI guideline was well accepted by the medical and public health communities, but concerns and criticisms arose as new evidence became available since the publication of the original guidelines. KDIGO (Kidney Disease: Improving Global Outcomes) recently published an updated guideline to clarify the definition and classification of CKD and to update recommendations for the evaluation and management of individuals with CKD based on new evidence published since 2002. The primary recommendations were to retain the current definition of CKD based on decreased glomerular filtration rate or markers of kidney damage for 3 months or more and to include the cause of kidney disease and level of albuminuria, as well as level of glomerular filtration rate, for CKD classification. NKF-KDOQI convened a work group to write a commentary on the KDIGO guideline in order to assist US practitioners in interpreting the KDIGO guideline and determining its applicability within their own practices. Overall, the commentary work group agreed with most of the recommendations contained in the KDIGO guidelines, particularly the recommendations regarding the definition and classification of CKD. However, there were some concerns about incorporating the cause of disease into CKD classification, in addition to certain recommendations for evaluation and management.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Estimated glomerular filtration rate (eGFR); Kidney Disease Quality Outcomes Quality Initiative (KDOQI); Kidney Disease: Improving Global Outcomes (KDIGO); albuminuria; chronic kidney diseases (CKD) staging; clinical practice guideline; kidney disease progression

Mesh:

Year:  2014        PMID: 24647050     DOI: 10.1053/j.ajkd.2014.01.416

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  465 in total

Review 1.  Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD.

Authors:  Hazel H Szeto
Journal:  J Am Soc Nephrol       Date:  2017-08-04       Impact factor: 10.121

Review 2.  Exploring the genetic basis of early-onset chronic kidney disease.

Authors:  Asaf Vivante; Friedhelm Hildebrandt
Journal:  Nat Rev Nephrol       Date:  2016-01-11       Impact factor: 28.314

3.  Clinical and hematological data to group different chronic kidney disease patients: A practical approach to establish different groups of patients.

Authors:  Vinícius B Péterle; Jéssica de O Souza; Fernanda de O Busato; Frederico J Eutrópio; Gisele de A P da Costa; David N Olivieri; Carlos E Tadokoro
Journal:  J Clin Lab Anal       Date:  2018-01-04       Impact factor: 2.352

4.  Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy.

Authors:  Rodrigo B Interiano; Noel Delos Santos; Sujuan Huang; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel M Green; Andrew M Davidoff
Journal:  Cancer       Date:  2015-04-01       Impact factor: 6.860

5.  Sex Hormones and Measures of Kidney Function in the Diabetes Prevention Program Outcomes Study.

Authors:  Catherine Kim; Ana C Ricardo; Edward J Boyko; Costas A Christophi; Marinella Temprosa; Karol E Watson; Xavier Pi-Sunyer; Rita R Kalyani
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

6.  Personalized medicine in chronic kidney disease by detection of monogenic mutations.

Authors:  Dervla M Connaughton; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

7.  Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Authors:  Rachel Gavish; Salmas Watad; Nathalie Ben-Califa; Ori Jacob Goldberg; Orly Haskin; Miriam Davidovits; Gili Koren; Yafa Falush; Drorit Neumann; Irit Krause
Journal:  Pediatr Nephrol       Date:  2018-07-20       Impact factor: 3.714

8.  Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.

Authors:  Fatemeh Ghane Sharbaf; Farahnak Assadi
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

9.  Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis.

Authors:  Evangelos Cholongitas; Ioannis Goulis; Maria Ioannidou; Stergios Soulaidopoulos; Parthenis Chalevas; Evangelos Akriviadis
Journal:  Hepatol Int       Date:  2016-08-30       Impact factor: 6.047

10.  Lifetime Risk of Stage 3-5 CKD in a Community-Based Sample in Iceland.

Authors:  Lesley A Inker; Hocine Tighiouart; Thor Aspelund; Vilmundur Gudnason; Tamara Harris; Olafur S Indridason; Runolfur Palsson; Shani Shastri; Andrew S Levey; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.